Navigation Links
Simplest therapeutic regimen found less effective against HIV

Antiretroviral therapy for treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection has improved steadily since the advent of combination therapy in 1996//. More recently, new drugs have been approved, offering added dosing convenience and improved safety profiles, while some previously popular drugs are being used less often as their drawbacks become better defined. Resistance testing is used more commonly in clinical practice and interactions among antiretroviral agents and with other drugs have become more complex. New government guidelines recommend against starting AIDS patients on a popular treatment combination, due to concerns that using two similar drugs can rapidly lead to treatment-resistant strains of HIV.

Therapeutic regimen that combines Videx and Viread with so-called "non-nuke" drugs like Sustiva is one of several treatment groupings that have led to the dramatic turn around against AIDS. In comparison to a litany of pills that HIV patients have to swallow to keep the virus under control, Videx and Viread, are a lot simpler to use, as they have to be taken just once a day.

However, recent studies have shown that HIV quickly grows resistant to the drugs when all three are used at once, possibly because Videx and Viread attack the disease in a like-minded fashion, and so, the Department of Health and Human Services is urging newly diagnosed patients to relinquish therapies that specifically combine these three. The new ‘Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents’ have been published, dated October 6, 2005.

Dr. Roy Gulick, an HIV specialist who helped establish the new guidelines, states that when two similar drugs are used together, they tend to mimic each other and fail. Despite falling short initially, Gulick said that the combination could still be used if other options prove unsuccessful. The new guidelines reflect the broad choice in AIDS treatment, listing the pr
'"/>




Page: 1 2

Related medicine news :

1. Tetanus causing toxin has therapeutic properties
2. Mice model to study bacterial therapeutic pathway
3. Hormone regimen and how recently used may determine cancer risk
4. Protective regimen for acute Graft-versus-host disease
5. Distraction therapy found very effective in postoperative patients
6. Antioxidants found in chocolates
7. Hidden influenza virus protein found
8. Scientists found ancient Human Germ Killer
9. Chewing gum found to increase brainpower
10. Ulcer causing bug found in stored food
11. Antioxidants found in chocolates

Post Your Comments:
(Date:11/8/2009)... USAction this evening ...merica Act, which will make health care more affor...untable and increase access to health care for mil..."Teddy Roosevelt, FDR and Harry Truman would be pr... "Today,s vote ranks among our country,s proudest ...
(Date:11/8/2009)... The following was rele...escue Insurrecta Nex. ,, Mr. Terry and his ass... to keep child-killing by abortion out of any heal...This is a great first step to victory -- a touchdo...ghting ahead of us. Our rejoicing must be tempered...
(Date:11/8/2009)...e Passage of Health Care Reform Bill ,, Criti... coverage for all Americans ,, BALTIMORE, Nov....he United States House of Representatives passed c...strengthen Medicare for seniors and end discrimina...f Americans out of affordable health coverage. ,...
(Date:11/7/2009).... 7 Speaker Nancy Pelo...R. 3962, the Affordable Health Care for America Ac...onight. Below are the Speaker,s remarks. ,, "...ic moment for our nation and for American families...d political philosophy -- as far back as Teddy Roo...
(Date:11/7/2009)...man (CT), David A. Cook (GA), Louis J. Goodman (TX...red ,, CHICAGO, Nov. 7 /PRNewswire-USNewswire/...resented five medical society executive leaders wi... to the goals and ideals of the medical profession...al policy making meeting in Houston. ,, (Logo:...
Breaking Medicine News(10 mins):Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA Honors Medical Society Executives 2
...hird quarter includes $1.8 million of first year ...mmercial products, DUBLIN, Calif., Oct. 29 Super...y dedicated to the discovery, rapid,development an...hs ended September 30, 2007. The Company reported...
...er reasons to avoid the habit, experts say , ... unhealthy in many other ways, but smoking does no...t cancer will have more aggressive or later-stage ... 35 years. , "Smoking did not affect treatment opt...
...ics Important to Detect, Diagnose and,Personalize ...or Congressional staff and the media on th...g diseases that disproportionately impact ...ght earlier and managed more effectively, ...
...The federal government has,approved all of BlueCro...vantage and Medicare Part D product offerings. Enr...ov. 15. BlueCross, products include two PPO plans...) Rx and MedBlue(SM) Rx,Plus. The plans include n...
... 29 Hovione,s Technology,Transfer Center (TTC) in...roval inspection by FDA. The inspection was carri...ficer at the US FDA Center for Drug Evaluation and...ad several positive,comments on our systems and in...
...nges Modern Psychology and Explodes Myths of ,Why ...NA BEACH, Fla., Oct. 29 Some children have a,gene...fficult to raise than,others. The notion of ,there.... For years, classical and modern,psychology sugge...
Other Medicine News:Health News:SuperGen Reports 2007 Third Quarter Financial Results 2Health News:SuperGen Reports 2007 Third Quarter Financial Results 3Health News:SuperGen Reports 2007 Third Quarter Financial Results 4Health News:SuperGen Reports 2007 Third Quarter Financial Results 5Health News:SuperGen Reports 2007 Third Quarter Financial Results 6Health News:SuperGen Reports 2007 Third Quarter Financial Results 7Health News:SuperGen Reports 2007 Third Quarter Financial Results 8Health News:SuperGen Reports 2007 Third Quarter Financial Results 9Health News:SuperGen Reports 2007 Third Quarter Financial Results 10Health News:Smoking Does Not Worsen Breast Cancer 2Health News:Smoking Does Not Worsen Breast Cancer 3Health News:AdvaMed Convenes Panel to Address Health Disparities 2Health News:FDA Inspects Hovione's Technology Transfer Center in New Jersey 2Health News:Bad Children Can Happen to Good Parents: A Survival Manual for Parents of Difficult Children by Norman E. Hoffman, Ph.D. 2Health News:Bad Children Can Happen to Good Parents: A Survival Manual for Parents of Difficult Children by Norman E. Hoffman, Ph.D. 3
(Date:11/6/2009)...TA, Nov. 6 GeoVax Labs,...e Company"), an Atlanta-based, biopharmaceutical c...ed by HIV-1 (Human Immunodeficiency Virus) and oth...arter 2009 financial results and provided an opera...ent and Chief Executive Officer commented, "We are...
(Date:11/6/2009)...IEGO, Nov. 6 California American W...s "No Drugs Down the Drain" week for its San Diego...n sponsored by public and private agencies alike t...l pollution in our source water supplies. ,, Ca...rs are encouraged to drop off expired or unwanted ...
(Date:11/5/2009)...IEGO, Nov. 5 Althea Technologies,...acturing services for biopharmaceutical products a...velopment to the company,s platform of services, w...ames Matsuura, Director of Formulation Development...ation and analytical scientists, along with new la...
Breaking Medicine Technology:GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29 2009 5323 1Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29 2009 5323 2Hutchinson Center scientists net 2416 7 million for stem cell research 59136 1Hutchinson Center scientists net 2416 7 million for stem cell research 59136 2Elderly immune system needs a boost 59134 1Elderly immune system needs a boost 59134 2
... 12 Boston,Scientific Corporation (NYSE: BSX ) t...7,500 patients from its TAXUS ARRIVE 1 and 2 regis...ce of the TAXUS(R) Express2(TM),Paclitaxel-Eluting...,two-year pooled ARRIVE data showed that the TAXUS...h diabetes as effectively as in patients without,d...
...entific,Corporation (NYSE: BSX ) today announced ...ss announcements at the Cardiovascular Research Fo...rdiovascular Therapeutics (TCT),scientific symposi..., D.C., Boston Scientific will be announcing a wi...R) Express2(TM) and second-generation TAXUS(R),Lib...
Other Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
Giardia lamblia II EIA
Medicine Products: